Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atazanavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.94 |
| ▸ | MLNR | O43193 | 1/20 | 0.94 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.94 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.94 |
| ▸ | CCKAR | P32238 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | GHSR | Q92847 | 1/20 | 0.94 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.94 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.94 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | CTSD | P07339 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | PGC | P20142 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atazanavir SCHEMBL29362158 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL27785902 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL291519 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL28121836 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL825777 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL7993264 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123654-A1 | COMPOSITIONS AND THERAPEUTIC USES OF CANNABIDIOL | MERCHANT, Shreema (CA) | 2023-04-20 | — | — | US | claimed |
| EP-4106870-A1 | COMPOSITIONS AND THERAPEUTIC USES OF CANNABIDIOL | Merchant, Shreema (CA) | 2022-12-28 | — | — | EP | claimed |
| US-20190125875-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | claimed |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | claimed |
| US-20150320731-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | claimed |
| US-20150080399-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2015-03-19 | — | — | US | claimed |
| EP-2170292-B1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2014-01-08 | — | — | EP | claimed |
| US-20110189297-A1 | STABLE SOLID ORAL DOSAGE CO-FORMULATIONS | Sequicia Pharmaceuticals (US) | 2011-08-04 | — | — | US | claimed |
| EP-2337565-A1 | STABLE SOLID ORAL DOSAGE CO-FORMULATIONS | Sequoia Pharmaceuticals (US) | 2011-06-29 | — | — | EP | claimed |
| EP-2178513-B1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2011-03-30 | — | — | EP | claimed |
| US-20100183716-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | Bristo-Meyers Squibb Company | 2010-07-22 | — | — | US | claimed |
| US-20100178340-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | claimed |
| US-20100178339-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | claimed |
| EP-2178512-A2 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | Bristol-Myers Squibb Company (US) | 2010-04-28 | — | — | EP | claimed |
| EP-2178511-A2 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | Bristol-Myers Squibb Company (US) | 2010-04-28 | — | — | EP | claimed |
| EP-2178513-A2 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | Bristol-Myers Squibb Company (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2010033614-A1 | STABLE SOLID ORAL DOSAGE CO-FORMULATIONS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-25 | — | — | WO | claimed |
| WO-2009002829-A2 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | claimed |
| WO-2009002823-A2 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | claimed |
| WO-2009002826-A2 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183716-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-20110189297-A1 | STABLE SOLID ORAL DOSAGE CO-FORMULATIONS | CYP3A5, CYP3A43, CYP3A7 | UGT1A1 50/4885MLNR 2427/4885NR1I2 899/4885 |
| US-20190125875-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | ACIN1, SAMHD1, ARSA | UGT1A1 2092/4885MLNR 2550/4885NR1I2 3993/4885 |
| US-20100178339-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-20150320731-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-20100178340-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-20150080399-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT | ACIN1, SAMHD1, ARSA | UGT1A1 2092/4885MLNR 2550/4885NR1I2 3993/4885 |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | ACIN1, SAMHD1, ARSA | UGT1A1 2092/4885MLNR 2550/4885NR1I2 3993/4885 |
| US-20230123654-A1 | COMPOSITIONS AND THERAPEUTIC USES OF CANNABIDIOL | SCN5A, CACNG5, TRPV1 | UGT1A1 1745/4885MLNR 3419/4885NR1I2 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.